Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
1373 studies found for:    Ovarian Cancer: Clinical Trials
Show Display Options
Rank Status Study
21 Terminated Clinical Trial for Ovarian Cancer (OvaRex®)
Condition: Ovarian Cancer
Intervention: Drug: oregovomab
22 Recruiting CT Antigen TCR-redirected T Cells for Ovarian Cancer.
Condition: Ovarian Cancer
Intervention: Biological: NYESO-1c259 T cells
23 Recruiting Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
Conditions: Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
Interventions: Drug: Paclitaxel(intravenous) + Carboplatin(intravenous);   Drug: Paclitaxel(intravenous) + Carboplatin(intraperitoneal)
24 Recruiting The Efficacy of Involved-field Radiation Therapy for Residual or Locoregionally Recurrent Epithelial Ovarian Cancer After Definitive Treatment; Multi-institutional Clinical Trial
Condition: Ovarian Cancer (Epithelial)
Intervention: Radiation: involved-field radiation therapy
25 Recruiting A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Device: ThermalCore Hyperthermia System
26 Completed
Has Results
BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: Paclitaxel;   Drug: Gemcitabine;   Drug: Topotecan;   Drug: Pegylated liposomal doxorubicin (PLD);   Drug: BI 6727
27 Terminated Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer;   Bowel Obstruction
Interventions: Drug: Cisplatin;   Drug: Paclitaxel
28 Terminated
Has Results
Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients
Condition: Ovarian Cancer
Interventions: Biological: Abagovomab;   Biological: Placebo
29 Active, not recruiting Phase 3 Trial of Maintenance Vigil for High Risk Stage IIIb-IV Ovarian Cancer
Conditions: Ovarian Cancer;   Ovarian Neoplasms
Interventions: Biological: Vigil;   Biological: Placebo
30 Active, not recruiting A Multicenter Trial On The Utility and Impact Of Computed Tomography and Serum CA-125 In the Management of Newly Diagnosed Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Other: CA 125 and CT scan
31 Terminated Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients
Condition: Recurrent Epithelial Ovarian Cancer
Intervention: Biological: DC-006 vaccine
32 Completed A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer
Intervention: Biological: DCVac-L
33 Completed
Has Results
A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer
Conditions: Epithelial Ovarian Cancer;   Extraovarian Peritoneal Cancer;   Fallopian Tube Carcinoma
Intervention: Drug: Ontak
34 Active, not recruiting Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
Condition: Recurrent Ovarian Cancer
Intervention: Drug: LDE225
35 Terminated
Has Results
A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer
Conditions: Epithelial Ovarian Cancer;   Extraovarian Peritoneal Cancer;   Fallopian Tube Carcinoma
Intervention: Drug: Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2a
36 Active, not recruiting Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Intervention: Procedure: Tumor collection
37 Completed Assess Cancer in Ovarian Tumors With Biomarkers.
Condition: Ovarian Tumor
Intervention: Procedure: Blood Draw
38 Completed Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor
Conditions: Platinum Refractory Epithelial Ovarian Cancer;   Primary Cancer of the Peritoneum;   Cancer of the Fallopian Tube
Interventions: Drug: Sunitinib;   Drug: SUNITINIB
39 Active, not recruiting Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer
Conditions: Ovarian Cancer;   Endometrial Cancer;   Fallopian Cancer;   Peritoneal Cancer
Interventions: Biological: E39 peptide vaccine;   Other: Clinical tracking for disease progression/recurrence
40 Active, not recruiting A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women
Condition: Epithelial Ovarian Cancer
Interventions: Procedure: CA125 assay on Abbott Architect i1000SR platform;   Procedure: HE4 assay on Architect i1000SR platform;   Procedure: Transvaginal Ultrasound

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.